Filing Flows › Haemonetics (HAE) › Q3 FY26
Haemonetics (HAE) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Feb 5, 2026
Haemonetics (HAE) reported revenue of $339M for the third quarter fiscal 2026 (Q3 FY26), -3% from a year earlier and +4% from the quarter before. Operating margin was 19.9%, net earnings $44.7M (13.2% of revenue).
Haemonetics, Q3 FY26: revenue $339M (-3% year over year), operating margin 19.9%, net earnings $44.7M, operating cash flow $93.6M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $339M | +4% | -3% |
| Gross profit | $202M | +4% | +5% |
| Operating profit | $67.4M | +15% | +14% |
| Net earnings | $44.7M | +16% | +19% |
| Operating cash flow | $93.6M | -16% | +114% |
| Free cash flow | $87.2M | -18% | +148% |
What changed
Revenue was $339.0M in Q3 FY26, down 3% year over year and up 4% from the previous quarter. Hospital was the largest line at 42% of revenue. Blood Center lost $13.8M year over year (down 20%), 144% of the total change.
Gross margin was 59.7%, up 4.2 points from a year earlier. Operating profit was $67.4M, a 19.9% margin (up 2.9 points year over year). Operating expenses grew 0% against a revenue fall of 3%. Net earnings were $44.7M, up 19% year over year. The effective tax rate was 25.4%.
Operating cash flow was $93.6M (up 114% year over year), 209% of net earnings. Non-cash charges added back $27.4M of depreciation and amortization and $7.8M of share-based compensation. Working capital and other items added $13.6M. Capital expenditures of $6.3M left free cash flow of $87.2M.
Questions
What was Haemonetics' revenue in the third quarter fiscal 2026?
Haemonetics (HAE) reported revenue of $339M for the third quarter fiscal 2026 (Q3 FY26), -3% from a year earlier and +4% from the quarter before.
Was Haemonetics profitable in the third quarter fiscal 2026?
Operating profit was $67.4M (19.9% of revenue) and net earnings $44.7M.
Source: Haemonetics 10-Q on SEC EDGAR.